Literature DB >> 8985419

In vivo administration of interleukin-2 protects susceptible mice from Theiler's virus persistence.

E L Larsson-Sciard1, S Dethlefs, M Brahic.   

Abstract

In vivo administration of interleukin-2 (IL-2)-secreting tumor cells results in complete protection against persistent infection by Theiler's murine encephalomyelitis virus (TMEV) in susceptible DBA/2 mice. The IL-2-mediated protection was found to depend on the inoculum size as well as the timing of IL-2 administration. IL-2-treated and TMEV-infected mice displayed a three- to fourfold relative increase in virus-specific cytotoxic T-lymphocyte (CTL) precursors. Thus, we postulate that the persistence of TMEV infection in susceptible mice reflects limited numbers of relevant CTL precursors and their time course of induction and activation.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 8985419      PMCID： PMC191120     

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  21 in total

1.  H-2 Dd transgene suppresses Theiler's virus-induced demyelination in susceptible strains of mice.

Authors:  M Rodriguez; C S David
Journal:  J Neurovirol       Date:  1995-03       Impact factor: 2.643

2.  Theiler's virus infection in mice: an unusual biphasic disease process leading to demyelination.

Authors:  H L Lipton
Journal:  Infect Immun       Date:  1975-05       Impact factor: 3.441

3.  Class II-restricted T cell responses in Theiler's murine encephalomyelitis virus (TMEV)-induced demyelinating disease. II. Survey of host immune responses and central nervous system virus titers in inbred mouse strains.

Authors:  R J Clatch; H L Lipton; S D Miller
Journal:  Microb Pathog       Date:  1987-11       Impact factor: 3.738

4.  FVB mice transgenic for the H-2Db gene become resistant to persistent infection by Theiler's virus.

Authors:  A Azoulay; M Brahic; J F Bureau
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

5.  Characterization of Theiler's murine encephalomyelitis virus (TMEV)-specific delayed-type hypersensitivity responses in TMEV-induced demyelinating disease: correlation with clinical signs.

Authors:  R J Clatch; H L Lipton; S D Miller
Journal:  J Immunol       Date:  1986-02-01       Impact factor: 5.422

6.  Clonal specificity of concanavalin A-induced cytotoxic T lymphocytes.

Authors:  E L Larsson; A Beretta; M Ermonval
Journal:  Eur J Immunol       Date:  1985-04       Impact factor: 5.532

7.  Identification of the class I genes of the mouse major histocompatibility complex by DNA-mediated gene transfer.

Authors:  R S Goodenow; M McMillan; M Nicolson; B T Sher; K Eakle; N Davidson; L Hood
Journal:  Nature       Date:  1982-11-18       Impact factor: 49.962

8.  Class I-deficient resistant mice intracerebrally inoculated with Theiler's virus show an increased T cell response to viral antigens and susceptibility to demyelination.

Authors:  L C Pullen; S D Miller; M C Dal Canto; B S Kim
Journal:  Eur J Immunol       Date:  1993-09       Impact factor: 5.532

9.  Organization and evolution of D region class I genes in the mouse major histocompatibility complex.

Authors:  D Stephan; H Sun; K F Lindahl; E Meyer; G Hämmerling; L Hood; M Steinmetz
Journal:  J Exp Med       Date:  1986-05-01       Impact factor: 14.307

10.  On the thymus in the differentiation of "H-2 self-recognition" by T cells: evidence for dual recognition?

Authors:  R M Zinkernagel; G N Callahan; A Althage; S Cooper; P A Klein; J Klein
Journal:  J Exp Med       Date:  1978-03-01       Impact factor: 14.307
View more
  9 in total

1.  Prevalent class I-restricted T-cell response to the Theiler's virus epitope Db:VP2121-130 in the absence of endogenous CD4 help, tumor necrosis factor alpha, gamma interferon, perforin, or costimulation through CD28.

Authors:  A J Johnson; M K Njenga; M J Hansen; S T Kuhns; L Chen; M Rodriguez; L R Pease
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

2.  CD28 costimulatory blockade exacerbates disease severity and accelerates epitope spreading in a virus-induced autoimmune disease.

Authors:  K L Neville; M C Dal Canto; J A Bluestone; S D Miller
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

3.  An early, abundant cytotoxic T-lymphocyte response against Theiler's virus is critical for preventing viral persistence.

Authors:  S Dethlefs; M Brahic; E L Larsson-Sciard
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

Review 4.  Natural pathogens of laboratory mice, rats, and rabbits and their effects on research.

Authors:  D G Baker
Journal:  Clin Microbiol Rev       Date:  1998-04       Impact factor: 26.132

5.  High numbers of viral RNA copies in the central nervous system of mice during persistent infection with Theiler's virus.

Authors:  M Trottier; P Kallio; W Wang; H L Lipton
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

6.  Protection against lethal encephalomyocarditis virus infection in the absence of serum-neutralizing antibodies.

Authors:  Z C Neal; G A Splitter
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

7.  Deletion of beta-2-microglobulin ameliorates spinal cord lesion load and promotes recovery of brainstem NAA levels in a murine model of multiple sclerosis.

Authors:  Aleksandar Denic; Istvan Pirko; Bharath Wootla; Allan Bieber; Slobodan Macura; Moses Rodriguez
Journal:  Brain Pathol       Date:  2012-03-08       Impact factor: 6.508

Review 8.  Theiler's virus infection: a model for multiple sclerosis.

Authors:  Emilia L Oleszak; J Robert Chang; Herman Friedman; Christos D Katsetos; Chris D Platsoucas
Journal:  Clin Microbiol Rev       Date:  2004-01       Impact factor: 26.132

9.  CD8-deficient SJL mice display enhanced susceptibility to Theiler's virus infection and increased demyelinating pathology.

Authors:  W S Begolka; L M Haynes; J K Olson; J Padilla; K L Neville; M Dal Canto; J Palma; B S Kim; S D Miller
Journal:  J Neurovirol       Date:  2001-10       Impact factor: 2.643
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.